Definition and epidemiology
Akathisia (from Greek, "not to sit") is a syndrome of subjective inner restlessness combined with observable semi-purposeful movements such as rocking from foot to foot, pacing, or an inability to keep the legs still. It is classified under drug-induced extrapyramidal syndromes.
- Occurs in roughly 20-45% of patients treated with first-generation (typical) antipsychotics.
- Lower but still clinically significant rates (approximately 5-15%) occur with second-generation (atypical) antipsychotics, with risk varying by agent (higher with aripiprazole and risperidone relative to quetiapine or olanzapine).
- Also reported with dopamine-blocking antiemetics (metoclopramide, prochlorperazine) and less commonly with SSRIs.
- Can occur in any age group; no strong sex predominance, though some studies suggest slightly higher rates in women.
- Onset is usually acute, within hours to weeks of starting or increasing a dopamine antagonist, but tardive and withdrawal forms also exist.
- Akathisia = subjective inner restlessness + objective repetitive movements, caused by dopamine D2 receptor blockade
- Classic trap: mistaking akathisia for psychotic agitation and increasing the antipsychotic dose, which worsens symptoms
- Highest risk with high-potency typical antipsychotics (haloperidol); also caused by metoclopramide
- Low ferritin/iron deficiency is an established risk factor
- First-line treatment: propranolol (beta-blocker); benzodiazepines are a useful adjunct
- Anticholinergics help parkinsonism/dystonia more than akathisia
- Barnes Akathisia Rating Scale (BARS) is the standard assessment tool
- Akathisia is a major cause of antipsychotic non-adherence and is linked to suicidality
Etiology and risk factors
The hallmark cause is dopamine D2 receptor blockade, most commonly from antipsychotic medications.
Common causative agents
- First-generation antipsychotics: haloperidol, fluphenazine (highest risk)
- Second-generation antipsychotics: aripiprazole, risperidone, ziprasidone (moderate risk); quetiapine, clozapine (lower risk)
- Antiemetics: metoclopramide, prochlorperazine, promethazine
- Antidepressants: SSRIs (less common, milder)
- Tetrabenazine and other dopamine-depleting agents
- Abrupt withdrawal of dopamine agonists or benzodiazepines
Risk factors
- High-potency, high-dose, or rapidly titrated dopamine antagonists
- Intravenous or intramuscular route (faster, higher peak dopamine blockade)
- Iron deficiency (low ferritin is associated with increased risk, likely via dopaminergic pathways)
- Concurrent mood disorder or anxiety
- Prior history of akathisia
- Older age may increase risk of some extrapyramidal syndromes, though akathisia itself can occur across ages
Pathophysiology
The precise mechanism is incompletely understood, but the leading model centers on dopaminergic blockade in the mesocortical and nigrostriatal pathways, disrupting the balance between dopaminergic and other neurotransmitter systems.
- D2 receptor antagonism in the ventral striatum and mesocortical circuits is thought to disrupt the normal regulation of motor planning and reward-related motivation, producing an intolerable urge to move.
- Noradrenergic hyperactivity has also been implicated, which is part of the rationale for beta-blocker therapy.
- Serotonergic pathways (5-HT2A) may modulate dopamine release and contribute, explaining why some antidepressants and atypical antipsychotics with serotonergic activity can both cause and sometimes modulate akathisia.
- Low central iron stores may impair dopamine synthesis (iron is a cofactor for tyrosine hydroxylase), another proposed contributing mechanism.
- Unlike parkinsonism, which reflects striatal dopamine depletion causing bradykinesia, akathisia appears to involve a more complex dysregulation producing hyperkinetic restlessness rather than simple hypokinesia.
Clinical features
Akathisia has both a subjective component (how the patient feels) and an objective component (what the examiner observes).
Subjective symptoms
- Inner restlessness, an urge to move described as unbearable
- Anxiety, irritability, dysphoria
- Feeling of "wanting to jump out of my skin"
- Insomnia
Objective signs
- Repetitive movements of the legs: rocking, marching in place, shifting weight
- Pacing that cannot be voluntarily suppressed for long
- Unable to sit or stand still; constant shifting in the chair
- Movements typically disappear with distraction only briefly and return
Key distinguishing clue
- Patients can describe why they are moving (an irresistible urge), unlike tics or chorea, which are often not goal-directed or purposeful in the same way.
- Severity ranges from mild subjective unease to severe agitation associated with increased suicidal ideation and aggression in extreme cases.
Diagnosis
Diagnosis is clinical, based on history (recent dopamine antagonist exposure) and recognition of the characteristic restlessness.
Approach
- Detailed medication history, including timing of any new drug or dose increase
- Barnes Akathisia Rating Scale (BARS) is the standard clinically validated tool, scoring objective movements, subjective awareness, subjective distress, and global severity
- Physical exam focused on movement pattern and ability to voluntarily suppress symptoms
- Check serum ferritin if low iron is suspected as a contributing factor
- Rule out other causes of agitation (withdrawal states, hyperthyroidism, primary anxiety or psychotic exacerbation)
| Feature | Akathisia | Psychotic agitation |
|---|---|---|
| Patient insight | Aware of inner restlessness, can describe urge | Often lacks insight, agitation tied to delusions/hallucinations |
| Movement | Rhythmic leg movements, pacing | Variable, less patterned |
| Response to antipsychotic increase | Worsens | May improve |
Differential diagnosis
- Psychotic or anxious agitation — underlying psychiatric worsening rather than drug effect; distinguished by lack of the specific urge-to-move quality and by temporal relationship to dose changes
- Restless legs syndrome — occurs predominantly at rest, worse in the evening/night, relieved by movement, not necessarily drug-induced
- Tardive dyskinesia — choreiform, repetitive orofacial and limb movements, usually not associated with the subjective urge to move seen in akathisia
- Parkinsonism (drug-induced) — bradykinesia, rigidity, tremor; opposite motor phenotype from akathisia's hyperkinetic restlessness
- Serotonin syndrome — fever, clonus, hyperreflexia, autonomic instability in addition to restlessness; more acute and severe
- Generalized anxiety disorder — psychological restlessness without the compulsive motor component or clear drug trigger
Management
The cornerstone of management is addressing the causative agent, with pharmacologic treatment as adjunct.
Step 1: Address the offending drug
- Reduce the dose of the causative antipsychotic or antiemetic if clinically feasible
- Switch to an agent with lower akathisia liability (e.g., quetiapine or olanzapine instead of a high-potency typical agent or aripiprazole), guided by psychiatric indication
- Avoid simply increasing the antipsychotic dose in response to apparent "agitation," a common and dangerous error
Step 2: Pharmacologic treatment (per APA and major psychiatric guideline consensus)
- Beta-blockers (propranolol) — first-line, best evidence, especially for acute akathisia
- Benzodiazepines (lorazepam, clonazepam) — effective adjunct, particularly when anxiety is prominent
- Anticholinergics (benztropine, trihexyphenidyl) — more effective for parkinsonism/dystonia than akathisia, but sometimes tried
- Mirtazapine (low dose) — supported by some trial evidence as an alternative agent
- 5-HT2A antagonism via agents like cyproheptadine has also shown benefit in some studies
Step 3: Correct contributing factors
- Replace iron if ferritin is low
Special situations
- Antiemetic-induced akathisia (e.g., from metoclopramide) usually resolves with drug discontinuation; diphenhydramine or benzodiazepine can be used for acute symptomatic relief
- Tardive akathisia (delayed onset, persisting after years of treatment) is more resistant and may require switching to clozapine, which has a lower propensity to cause extrapyramidal syndromes
Complications and prognosis
- Acute akathisia usually resolves within days to weeks after dose reduction, discontinuation, or switching the causative agent
- Untreated or unrecognized akathisia is associated with poor medication adherence, as the distress often leads patients to stop treatment
- Severe akathisia has been linked to increased risk of suicidal ideation, self-harm, and aggression, making prompt recognition clinically important
- Chronic/tardive akathisia can persist even after stopping the offending drug and is generally more difficult to treat
- With appropriate management, prognosis for acute akathisia is favorable; tardive forms carry a more guarded prognosis
"RESTLESS": Rocking/pacing, Extrapyramidal cause (dopamine blockers), Subjective urge to move, Treat with propranolol, Low ferritin a clue, Easily mistaken for agitation, SSRIs can also cause it, Stop/switch the offending drug.
Practice questions
1. A 34-year-old man with schizophrenia is started on haloperidol for an acute psychotic episode. Three days later, he appears unable to sit still, constantly shifting his weight and pacing the hallway. He reports feeling an unbearable urge to keep moving and says it is "driving him crazy." His psychiatrist suspects his psychosis is worsening and increases the haloperidol dose. The following day his restlessness is markedly worse. Which of the following is the most appropriate next step?
2. A 58-year-old woman receiving metoclopramide for diabetic gastroparesis develops an intense urge to move her legs and cannot remain seated during her clinic visit. She denies anxiety or psychiatric history. Laboratory workup reveals a low serum ferritin. Which of the following is the most appropriate initial management?
3. A 45-year-old man on long-term risperidone for bipolar disorder develops persistent restlessness and repetitive leg movements that have continued for several months despite dose reduction and a trial of propranolol. He has been on antipsychotic therapy for over three years. Which of the following best describes his condition and the most appropriate next step?
Frequently asked questions
What causes akathisia?
Akathisia is most commonly caused by drugs that block dopamine D2 receptors, especially antipsychotics (both first- and second-generation) and dopamine-blocking antiemetics like metoclopramide. It can also occur with SSRIs and after abrupt withdrawal of dopaminergic or benzodiazepine medications. Risk increases with higher drug potency, rapid dose escalation, and low iron stores.
What are the first symptoms of akathisia?
The earliest symptom is usually a vague sense of inner restlessness or unease that the patient struggles to describe, soon followed by an irresistible urge to move the legs. This progresses to visible rocking, shifting weight from foot to foot, or pacing, typically appearing within hours to a few weeks of starting or increasing a dopamine-blocking medication.
How is akathisia diagnosed?
Akathisia is diagnosed clinically through history of recent dopamine antagonist exposure combined with characteristic subjective restlessness and observable repetitive leg movements. Clinicians often use the Barnes Akathisia Rating Scale to standardize assessment. No lab test confirms the diagnosis, though checking ferritin can identify a contributing, correctable risk factor.
Is akathisia curable?
Yes, acute akathisia is generally reversible and resolves within days to weeks after lowering the dose, switching, or stopping the causative drug, often aided by propranolol or a benzodiazepine. Tardive akathisia, which develops after prolonged treatment, is more persistent and harder to fully reverse, sometimes requiring a switch to clozapine.
Akathisia vs restless legs syndrome — what is the difference?
Akathisia is drug-induced, can occur at any time of day, and involves a generalized urge to move the whole body, often in a patient recently started on an antipsychotic. Restless legs syndrome occurs predominantly at rest, worsens in the evening or night, is confined mainly to the legs, and is relieved by movement, without necessarily being linked to a dopamine-blocking drug.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: G21.1
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.